Left Ventricular Assist Device as Bridge to Recovery for Anthracycline‐Induced Terminal Heart Failure

©2012 Wiley Periodicals, Inc. Anthracycline treatments are hampered by dose‐related cardiotoxicity, frequently leading to heart failure (HF) with a very poor prognosis. The authors report a case of a 19‐year‐old man developing HF after anthracycline treatment for Ewing sarcoma. Despite medical treat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Congestive heart failure (Greenwich, Conn.) Conn.), 2012-09, Vol.18 (5), p.291-294
Hauptverfasser:	Appel, Jon M., Sander, Kåre, Hansen, Peter B., Møller, Jacob E., Krarup‐Hansen, Anders, Gustafsson, Finn
Format:	Artikel
Sprache:	eng
Schlagworte:	Anthracyclines - adverse effects Antineoplastic Agents - adverse effects Cardiotoxins - adverse effects Heart Failure - chemically induced Heart Failure - pathology Heart Failure - therapy Heart Transplantation Heart Ventricles - innervation Heart Ventricles - pathology Heart-Assist Devices Humans Male Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	©2012 Wiley Periodicals, Inc. Anthracycline treatments are hampered by dose‐related cardiotoxicity, frequently leading to heart failure (HF) with a very poor prognosis. The authors report a case of a 19‐year‐old man developing HF after anthracycline treatment for Ewing sarcoma. Despite medical treatment, his condition deteriorated to terminal HF, leading to implantation of a mechanical left ventricular assist device (LVAD). His heart function recovered, allowing explantation of the device 14 months after implantation. Heart transplantation is often contraindicated in the first years after treatment for cancers, and LVAD as “bridge to recovery” may be warranted in similar patients.
ISSN:	1527-5299 1751-7133
DOI:	10.1111/j.1751-7133.2012.00291.x